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1 Background 
1.1 Drug  
Generic/Brand name: Panitumumab/Vectibix® 
Developer/Company: Amgen 
Description: Panitumumab is a fully human monoclonal antibody. It is 
designed to specifically attach to the antigen epidermal growth factor 
receptor (EGFR), which can be found on the surface of certain cells, 
including tumour cells. By targeting the EGFR, the tumour cells no longer 
receive the information needed for growth, progression and spreading. 
Approximately 70-80% of patients with advanced colorectal cancer (CRC) 
overexpress EGFR [1]. Panitumumab does not work in tumour cells that 
contain the mutated (MT) KRAS gene, because the growth of these cells is 
not controlled by signals transmitted by the EGFR. Thus, these cells 
continue to grow even when EGFR is blocked [2-3]. Consequently, 
panitumumab was recommended for the treatment of adult patients 
suffering from metastatic colorectal cancer (mCRC) with non-mutated 
KRAS genes, that is with a wild-type (WT) KRAS status, by the European 
Medicines Agency (EMA) [4].  
Application: 6mg/kg panitumumab are administered via intravenous infu-
sion once every two weeks [4].  
1.2 Indication 
Panitumumab as 1st-line combination therapy with FOLFOX (oxaliplatin, 5-
fluorouracil and folinic acid) for patients with wild-type KRAS metastatic 
colorectal cancer (WT KRAS mCRC) [1]. 
1.3 Burden of disease 
Colorectal cancer is one of the leading causes of cancer-deaths worldwide. Its 
primary risk factors are age >50 years, colorectal polyps, family history of 
colorectal cancer, personal history of cancer, genetic alterations, diets high 
in fat and low in calcium, folate and fiber and cigarette smoking [5]. Men 
are still more often affected by mCRC than women. 90% of the patients are 
diagnosed at an age of >50 years [6]. On average, patients are aged 70 years 
at the time of diagnosis of mCRC [7]. Initial symptoms in patients with 
CRC are abdominal pain, change in bowel habit, haematochezia or melena, 
weakness, anaemia without other gastrointestinal symptoms and weight loss. 
CRC is either diagnosed due to the presence of one or more of these 
signs/symptoms or by routine screening [8]. Approximately 20% [7] of pa-
tients are initially diagnosed with metastatic disease and 30-40% of CRC pa-
tients initially diagnosed with localized disease will develop metastatic dis-
ease [9]. 
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The TNM (tumour node metastasis) staging system is the preferred staging 
system for CRC and is based on the depth of invasion of the bowel wall, ex-
tent of regional lymph node involvement, and presence of distant sites of the 
disease [9]. Based on the determination of the T, N and M these three letters 
and their accompanying numbers are combined in an overall stage (0-IV). 
The exact TNM staging is described in more detail elsewhere [10]. Metas-
tatic colorectal cancer is classified as stage IV disease. Five-year survival rate 
for stage IV colorectal cancer is <10% [8-9]. Overall, pathologic stage of the 
disease is the most important prognostic factor [9]. 
Although panitumumab is a monoclonal antibody targeting the EGFR, evi-
dence suggests that EGFR expression is not a valid predictive factor for re-
sponse to panitumumab as also patients with low or negative EGFR expres-
sion benefit from EGFR inhibitors [11]. On the other hand, KRAS testing is 
strongly recommended prior to initiation of therapy, as only patients with 
WT KRAS respond to panitumumab therapy [11]. Thus, KRAS testing is es-
sential to identify patients eligible for panitumumab therapy and conse-
quently to spare patients which are unlikely to respond associated toxicities 
[12-13]. KRAS mutations are found in 30-50% of CRC tumours and are as-
sociated with tumours of more advanced stages, increased metastatic poten-
tial, poor prognosis and decreased progression-free survival (PFS) and over-
all survival (OS) [2-3]. Whereas, KRAS status is currently the only predic-
tive factor for response to anti-EGFR therapy, only 50% of patients with WT 
KRAS respond to anti-EGFR agents [13]. 
In Austria, 2200 people died of and 4460 (2450 men and 2010 women) pa-
tients were newly diagnosed with CRC in 2008 [14]. Applying the estimates 
mentioned above, approximately 960 patients are newly diagnosed with or 
progress to WT KRAS mCRC in Austria per year. 
1.4 Current treatment options 
Surgical resection is a potentially curative therapy of CRC [8], but only few 
patients with mCRC are eligible for resection in the first place or become re-
sectable after response to chemotherapy and shrinkage of their tumour 
(“conversion therapy”) [15-16]. Since the majority of mCRC patients suffer 
from unresectable disease the treatment goal then is palliative, aiming at 
prolonging OS and maintaining quality of life (QoL) for as long as possible 
[15]. In the past decade several new chemotherapeutic agents and novel tar-
geted drugs have been approved for the treatment of mCRC and have led to 
improved outcomes for patients with mCRC and to an increased number of 
therapeutic options [3]. 
Even though the majority of patients is asymptomatic at time of diagnosis, 
there is some evidence that chemotherapy should be initiated immediately 
after diagnosis rather than delaying therapy until they become symptomatic 
[15]. The optimal duration of the initial chemotherapy depends on tolerance 
of and response to chemotherapy, disease bulk and location and symptoma-
tology [15]. 
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Currently, the following five different classes of drugs are available for the 
treatment of non-operable mCRC: 
- Fluoropyrimidines (5-fluorouracil (5-FU)), usually given with leuco-
vorin, capecitabine, tegafur plus uracil 
- Irinotecan 
- Oxaliplatin 
- Cetuximab or panitumumab, two monoclonal antibodies designed to 
target the EGFR 
- Bevacizumab, a monoclonal antibody targeting VEGF [16]. 
The best way of combining and sequencing these agents has not been estab-
lished yet, but evidence indicates that exposing mCRC patients to all cy-
tostatic drugs is more important than a specific sequence of administration 
[16]. 
Although, no trial has yet compared the two EGFR-targeting agents cetuxi-
mab and panitumumab directly, cross-trial comparisons and preclinical data 
suggest that they do not only have a similar mode of action but they also ap-
pear to have comparable efficacy profiles [16]. Despite, there is no therapeu-
tic preference of using panitumumab rather than cetuximab in clinical prac-
tice, the lower rate of infusion reactions favour the use of panitumumab in 
regions with a high rate of cetuximab-related infusion reactions [16]. 
Generally, a doublet chemotherapy based on either oxaliplatin or irinotecan 
is recommended as the backbone of initial mCRC therapy. Further, the ad-
dition of bevacizumab to either oxaliplatin- or irinotecan-based regimens is 
recommended, but improved outcomes have to be balanced carefully against 
the potential for serious treatment-related toxicity. The addition of the 
EGFR-targeting agents cetuximab and panitumumab to irinotecan-based 
chemotherapy is only recommended for patients with WT KRAS tumours 
[16-18]. Due to insufficient evidence on the use of bevacizumab in the sec-
ond-line setting, its role as a component in a second-line regimens is not yet 
established [16, 19]. 
1.5 Current regulatory status 
Panitumumab was initially approved as a single-agent in the third-line ther-
apy of mCRC by the European Medicines Agency (EMA) in December 2007. 
In March 2011, the Committee for Human Medicinal Products (CHMP) 
adopted a negative opinion for the extension of indication of panitumumab 
as first- or second-line therapy in mCRC in combination with chemother-
apy. Reasons for this negative opinion were concerns about the clinical rele-
vance of the relatively small increase in PFS, lack of improvement in OS, in-
creased toxicity and the risk of MT KRAS patients being treated with pani-
tumumab if they could not be identified a priori through appropriate tests. 
After re-examination, the CHMP recommended the extension of indication 
for first- and second-line treatment of WT KRAS mCRC patients in June 
2011 [1]. The final approval by the European Commission is still awaited. 
Panitumumab is recommended for the following indications:  
- as monotherapy for the treatment of patients with EGFR expressing 
mCRC with WT KRAS after failure of previous chemotherapy regi-
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mens including fluoropyrimidine, oxaliplatin or irinotecan (condi-
tional approval) [20]. 
- as first-line therapy in combination with FOLFOX (oxaliplatin, 5-
fluorouracil and folinic acid) in WT KRAS mCRC [1]. 
- as second-line therapy in combination with FOLFIRI (irinotecan, 5-
flouorouracil and folinic acid) in WT KRAS mCRC patients who have 
already received fluoropyrimidine-based chemotherapy (excluding ir-
inotecan) [1]. 
The US Food and Drug Administration (FDA) approved panitumumab as 
monotherapy in WT KRAS mCRC patients who have progressed on or fol-
lowing fluoropyrimidine, oxaliplatin or irinotecan chemotherapy regimens 
in September 2006 [21-22]. 
1.6 Treatment costs  
Panitumumab is administered as an intravenous infusion (i.v.) once every 2 
weeks. The recommend dose is 6mg/kg [4]. In Austria, the price for one vial 
of 5ml containing 20mg/ml panitumumab is €425.- (manufacturer’s price 
[23]; pharmacy retail price: €707.- [24]). Assuming an average weight of 70kg 
of patients, 5 vials are needed for one treatment cycle of two weeks. There-
fore, estimated monthly treatment costs for panitumumab mono-therapy are 
€4,250.- (€7,072.-). 
Based on the evidence that EGFR-targeting agents are not effective in 
KRAS-mutated tumours, KRAS testing is required prior to panitumumab 
containing therapy regimens [1]. Thus, the costs of KRAS testing and pani-
tumumab are additional to the costs of chemotherapy. 
2 Evidence 
A literature search was conducted in the following electronic databases on 
the 3rd of August 2011: Cochrane Library, Ovid Medline, CRD Database and 
EMBASE. Search terms included panitumumab or vectibix combined with 
metastatic colorectal cancer, metastatic colorectal carcinoma, colorectal can-
cer, colorectal carcinoma, mCRC. After removing duplicates, 492 references 
were identified. Of those, only randomized controlled trials reporting results 
for WT KRAS mCRC patients treated with panitumumab in the first-line 
setting were included, yielding 4 relevant references reporting results from 2 
randomized controlled trials and two meta-analyses [3, 25-27]. 
In comparison to the initial HSS report [28], OS and safety data of the 
PRIME trial have been fully published in a paper [25]. In addition, two 
meta-analyses investigating the treatment effect of panitumumab in the 
first-, second- or subsequent lines of therapy of mCRC were published [3, 
27]. 
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2.1 Efficacy and safety - RCTs 
Table 1: Efficacy and safety results of phase III RCTs 
Reference  Douillard et al. 2010 [25], PRIME trial Hecht et al. 2009 [26], PACCE trial 
Sponsor Amgen, Thousand Oaks, CA Amgen Inc. 
Country 133 institutions in 19 countries USA, 200 centres 
Design randomized, open-label, multicentre, phase III trial randomized, open-label, multicentre, phase IIIb trial 
Hypothesis Superiority Superiority 
Number of patients 1,096 (I 546 vs C 550)  
1,053 (Ox-CT cohort 823 (I 413 vs C 410) vs Iri-CT cohort 
(230 (I 115 vs C 115)) 
Number of patients 
with WT KRAS/MT 
KRAS 
I 217/145 vs C 204/128 NR 
Treatment   
Intervention (I) 6 mg/kg panitumumab iv infusion every 2 weeks on day 1 before FOLFOX4 chemotherapy 
1. panitumumab + bevacizumab + Ox-CT (=fluorouracil, 
leucovorin and oxaliplatin-based chemotherapy) 
 
2. panitumumab + bevacizumab + Iri-CT (=fluorouracil, 
leucovorin and irinotecan-based chemotherapy) 
Control (C) 
FOLFOX 4 (every two weeks): oxaliplatin 85mg/m2 iv infu-
sion (day 1), leucovorin 200mg/m2 (or equivalent) iv infu-
sion followed by fluorouracil 400mg/m2 iv bolus and 
600mg/m2 22-hour continuous infusion on days 1 and 2 
1. bevacizumab +  Ox-CT (=fluorouracil, leucovorin and ox-
aliplatin-based chemotherapy) 
 
2. bevacizumab + Iri-CT (=fluorouracil, leucovorin and iri-
notecan-based chemotherapy) 
Inclusion criteria untreated mCRC (adenocarcinoma), ECOG PS 0-2 untreated mCRC, ECOG PS 0-1, adequate hematologic, he-patic and renal functions 
 Participants  
characteristics WT KRAS MT KRAS Ox-CT cohort Iri-CT cohort 
Median age years 
(range)  I 62 (27-85) vs C 61 (24-82) I 63 (33-83) vs C 61 (27-82) I 61 (28-88) vs C 62 (22-89) I 60 (35-84) vs C 59 (23-80)
Male (%) I 67 vs C 62 I 66 vs C 58 I 56 vs C 58 I 49 vs C 62 
ECOG PS 0-1 (%) I 94 vs C 94 I 96 vs C 95 I 100 vs C 100 I 100 vs C 100 
Prior adjuvant 
therapy I 16 vs C17 I 16 vs C 12 I 19 vs C 19 I 33 vs C31 
Colon cancer (%) I 66 vs C 65 I 68 vs C 73 NR NR 
Rectal cancer (%) I 34 vs C 35 I 32 vs C 27 NR NR 
WT KRAS (%) 60 39 43 
Follow-up I 13.2 vs C 12.5 months I 10.8 vs C 12 months 7.5* months 6.5* months 
OS     
Median (months) I 23.9 vs C 19.7 I 15.5 vs C 19.3 I 18.4 vs C not reached* NR 
HR 0.83 (95% CI 0.67 to 1.02; p=0.72) 
1.24 (95% CI 0.98 to 1.57; 
p=0.68) 1.56 (95% CI 1.11 to 2.19)* NR 
Subgroup analysis   
WT KRAS: HR=1.89 (95% CI 
1.30 to 2.75; p =0.045)** 
MT KRAS: HR=1.02 (95% CI 
0.67 to 1.54)** 
WT KRAS: HR=1.28 (95% CI 
0.5 to 3.25; p = 0.445)** 
MT KRAS: HR=2.14 (95% CI 
0.82 to 5.59)** 
PFS (primary outcome) (primary outcome) (secondary outcome) 
Median (months) I 9.6 vs C 8.0 I 7.3 vs C 8.8 I 8.8 vs C 10.5* I 10.1 vs C 11.9* 
HR 0.80 (95% CI 0.66 to 0.97; p=0.02) 
1.29 (95% CI 1.04 to 1.62; 
p=0.02) 
1.44 (95% CI 1.13 to 1.85; 
p=0.004)* 
1.57 (95% CI 0.71 to 3.46; 
p=NR)* 
Subgroup analysis   
WT KRAS: HR=1.36 (95% CI 
1.04 to 1.77)** 
MT KRAS: HR=1.25 (95% CI 
0.91 to 1.71)** 
WT KRAS: HR=1.5 (95% CI 
0.82 to 2.76)** 
MT KRAS: HR=1.19 (95% CI 
0.65 to 2.21)** 
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ORR (%) I 55 vs C 48 I 40 vs C 40 
I 46 vs C 48 
OR=0.92 (95% CI 0.7 to 
1.22)** 
I 43 vs C 40 
OR=1.11 (95% CI 0.65 to 
1.9)** 
PR (%) NR NR I 46 vs C 47** I 43 vs C 40** 
Subgroup analysis   WT KRAS: I 50 vs C 56** MT KRAS: I 47 vs C 44** 
WT KRAS: I 54 vs C 48** 
MT KRAS: I 30 vs C 38** 
Adverse events 
(AEs)   
WT KRAS MT KRAS Ox-CT Iri-CT 
Any grade (%)  
I C I C 
 
I C I C 
 
Patients with any event 
Neutropenia 
Skin toxicity 
Diarrhoea 
Neurologic toxicities 
Hypokalemia 
Fatigue 
Mucositis 
Hypomagnesaemia 
Paronychia 
Pulmonary embolism 
Febrile neutropenia 
Infusion-related reaction 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
Skin toxicity 
Diarrhoea 
Nausea/vomiting 
Infections 
Neutropenia 
Dehydration 
Hypomagnesemia 
Neuropathy 
Hypertension 
Paronychia 
Deep venous thrombosis 
Pulmonary embolism 
Gastrointestinal perforations 
95 
74 
71 
57 
36 
33 
28 
21 
18 
9 
7 
7 
<1 
30 
66 
75 
48 
43 
17 
2 
28 
21 
0 
8 
4 
0 
95 
83 
79 
58 
34 
29 
31 
- 
14 
14 
13 
12 
- 
26 
79 
74 
37 
33 
20 
4 
- 
20 
0 
6 
5 
- 
WT KRAS MT KRAS Ox-CT Iri-CT 
Grade ≥3 (%)  
I C I C 
 
I C I C 
 
Patients with any event 
Neutropenia 
Skin toxicity 
Diarrhoea 
Neurologic toxicities 
Hypokalemia 
Fatigue 
Mucositis 
Hypomagnesaemia 
Paronychia 
Pulmonary embolism 
Febrile neutropenia 
Infusion-related reaction 
84 
42 
36 
18 
16 
10 
9 
9 
6 
3 
3 
2 
<1 
69 
41 
2 
9 
16 
5 
3 
<1 
<1 
0 
2 
2 
- 
80 
37 
30 
20 
17 
9 
7 
6 
6 
2 
3 
3 
0 
73 
47 
1 
10 
17 
4 
5 
3 
<1 
0 
4 
3 
- 
Skin toxicity 
Diarrhoea 
Nausea/vomiting 
Infections 
Neutropenia 
Dehydration 
Hypomagnesemia 
Neuropathy 
Hypertension 
Paronychia 
Deep venous thrombosis 
Pulmonary embolism 
Gastrointestinal perforations 
36 
24 
13 
18 
24 
17 
4 
4 
4 
1 
7 
6 
0 
1 
13 
7 
10 
24 
6 
0 
7 
5 
0 
8 
4 
0 
38 
28 
13 
14 
17 
14 
5 
- 
2 
4 
13 
11 
- 
0 
9 
8 
9 
21 
6 
1 
- 
3 
0 
0 
5 
- 
Fatal AEs (%)  5 6 8 3  NR NR NR NR
Treatment related 
deaths (number of 
pts) 
 4 4 2 1  5 NR 2 NR
Notes 
EGFR expression and KRAS status were not required at en-
try 
Because of decreased PFS and increased toxicity in the pani-
tumumab-arm, panitumumab treatment was discontinued 
in March 2007 based on results of the planned interim 
analysis (October 2006). The trial continued without pani-
tumumab treatment. No further protocol-pre-specified hy-
pothesis testing was conducted. 
The reported results are from the planned interim analysis 
(October 2006) and a descriptive analysis of the efficacy 
and safety data available in March 2007. 
*Planned interim analysis of safety and efficacy at approximately 50% progression or death events in the Ox-CT cohort; data cutoff 
on October 30, 2006. 
**Analysis of the descriptive update of the primary analysis, May 2007 (panitumumab was discontinued by the sponsor in March 
2007) 
Abbreviations: ECOG PS – Eastern Cooperative Oncology Group Performance Status, OS – overall survival, PFS – progression free 
survival, ORR – objective response rate, PR – partial response, NR – not reported, 95% CI – 95% confidence interval, WT – 
wild-type, MT – mutant 
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PRIME trial [25] 
The PRIME trial was initially designed to compare the treatment effect of 
adding panitumumab to first-line FOLFOX compared to FOLFOX alone in 
all randomly assigned patients, regardless of their KRAS status. Due to 
evolving evidence that a mutational KRAS status is a negative predictive 
factor of the efficacy of panitumumab and cetuximab, the study was 
amended to compare PFS and OS according to the KRAS status of patients 
before any efficacy analyses were conducted. To ensure adequate power for 
PFS in the WT KRAS stratum, the required sample size was increased from 
900 to 1,150. KRAS status was analysed in 93% of the 1,183 patients finally 
enrolled. Of these, 60% had WT KRAS and 40% had MT KRAS tumours. 
The effect analysis by KRAS status showed a statistically significant prolon-
gation of median OS (HR = 0.57 (95% CI 0.46 to 0.71; p<0.001) in the WT 
stratum compared to the MT stratum in the panitumumab + FOLFOX arm. 
Within the control arm the HR for OS was 0.87 (95% CI 0.7 to 1.08; p=0.21) 
for the WT stratum versus the MT stratum. The objective response rate 
(ORR) was numerically higher in the intervention arm of the WT KRAS 
stratum compared to the control arm, but not statistically significant. By 
which extent ORR was achieved by partial or complete response is not re-
ported in the publication Patient characteristics were well balanced between 
the intervention and control groups [29]. As expected, AEs were more fre-
quent and more severe in the intervention arm regardless of KRAS status 
due to the addition of panitumumab to chemotherapy. Skin-related toxici-
ties occurred also more frequently and more severely in the panitumumab + 
FOLFOX arm (94%) compared to the FOLFOX arm (31%). PRIME and 
previous studies with EGFR monoclonal antibodies demonstrated an asso-
ciation between skin-related toxicities and the efficacy of EGFR-targeting 
monoclonal antibodies. 51% of patients in the WT KRAS stratum and 61% 
of patients in the MT KRAS stratum discontinued chemotherapy, mainly 
due to disease progression. 
 
PACCE trial [26] 
The underlying rationale of the PACCE trial was that the dual-pathway in-
hibition by combining two targeted agents with chemotherapy leads to an 
increase in antitumour activity. Results of a planned interim analysis 
showed that the addition of panitumumab to bevacizumab + chemotherapy 
led to decreased PFS and increased toxicity in the intervention arm. Thus, 
the administration of panitumumab was stopped in March 2007 and the trial 
continued per protocol, but without panitumumab. The updated descriptive 
analysis was conducted with data as of May 30, 2007. KRAS status was 
evaluated in 82% of patients of which 40% had mutations. PFS favoured the 
control arm in both chemotherapy cohorts regardless of KRAS status. Over-
all response rates were generally comparable between treatment arms. Only 
two patients in the control arm of the Ox-CT cohort reached complete re-
sponse, 43-47% of patients in all other groups had partial responses. In both 
chemotherapy cohorts AEs were more frequent and more serious in the 
panitumumab arm than in the control arm with 90% and 77% in the Ox-CT 
cohort, respectively and 90% versus 63% in the Iri-CT cohort, respectively. 
It is estimated, that about 19% had a panitumumab-related serious AE. Ac-
cording to the investigator assessment, 7 (1%) deaths were panitumumab-
related – 5 in the Ox-CT cohort and 2 in the Iri-CT cohort. 
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2.2 Efficacy and safety - further studies 
Petrelli et al. [27] conducted a meta-analysis to investigate whether panitu-
mumab and cetuximab in combination with chemotherapy are superior in 
terms of relative risk (RR) of response, PFS and OS in WT KRAS mCRC 
patients to chemotherapy alone. All in all, they included results of 7 ran-
domized controlled trials (RCTs) that analysed the treatment effect in WT 
KRAS mCRC patients. The main finding of this analysis was that both 
EGFR-targeting agents seemed to be more effective in second- or further 
lines of therapy than in the first-line setting. When treated with one of these 
two agents the chances of obtaining a response is 10-fold higher in second- 
or further lines of therapy compared to first-line therapy and even 30-fold 
higher compared to best supportive care alone (RR=33.84; p=0.0005). 
Whereas both drugs increased the RR of obtaining response and reduced the 
risk of progression in WT KRAS mCRC patients, the results were more ro-
bust in patients treated with panitumumab [27]. 
The meta-analysis published by Ibrahim et al. [3] aimed at quantifying the 
benefit and safety of panitumumab in WT KRAS mCRC patients. Four 
RCTs were included in the analysis – two in the first-line setting (PRIME 
and PACCE), one in the second-line treatment of mCRC patients and one 
after failure of several prior interventions. Confirming the findings of Pet-
relli et al. [27], this meta-analysis demonstrated that the positive treatment 
effect of panitumumab was more pronounced and statistically significant in 
second- or subsequent lines of therapy in WT KRAS mCRC patients, but no 
statistical significance in PFS and OS was found in the first-line setting. The 
findings in the first-line setting might result from the fact, that two studies 
were included of which one (the PACCE trial) was halted after the first in-
terim analysis due to a decrease in PFS and an increase in AEs caused by the 
combination of two monoclonal antibodies targeting different receptors. 
Overall, survival results might have been confounded by an unbalanced 
cross-over reported in three of the included trials [3].  
3 Commentary 
After an initial refusal of market authorization for first-line panitumumab 
in March 2011, the CHMP adopted a positive opinion for the extension of 
indication of panitumumab for the first -line treatment but only for WT 
KRAS mCRC patients in combination with FOLFOX in June 2011; MT 
KRAS was listed as a contraindication [1]. The final decision of approval is 
still pending.  
Limiting panitumumab to patients without KRAS mutations and only in 
combination with FOLFOX can be explained by two phase III RCTs (see 
Table 1): the PRIME trial compared panitumumab + FOLFOX with 
FOLFOX aloneand led to a 20% risk reduction of progression or death in 
patients with WT KRAS [25], whereas patients in the intervention group of 
the PACCE trial had worse efficacy outcomes and higher toxicities than the 
control group without panitumumab - regardless of their KRAS status. 
These findings underpinned that dual-pathway inhibition with different 
types of targeted agents is inferior to combining the VEGF-inhibitor bevaci-
meta-analysis on the 
effect of EGFR-targeting 
agents in mCRC 
treatment 
 
EGFR inhibitors are 
more effective in 2nd- 
and further lines of 
therapy than in the 1st-
line setting 
meta-analysis on the 
effect of panitumumab 
in mCRC treatment 
 
panitumumab is more 
effective in 2nd- or 
further lines of mCRC 
therapy than in 1st-line 
therapy 
June 2011: positive 
opinion for 1st- and 2nd-
line therapy 
contraindication: MT 
KRAS  
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zumab with chemotherapy (either FOLFIRI or FOLFOX) and is thus not 
recommended for mCRC treatment [26]. Other results favouring the addi-
tion of panitumumab to chemotherapy found in the PRIME trial were nu-
merically higher, but not statistically significant, median OS and ORR in 
the panitumumab + FOLFOX group compared to the FOLFOX group 
alone in the WT KRAS stratum. AEs were more frequent and more severe in 
the intervention group. Even though skin toxicities occurred more fre-
quently and more severely in the panitumumab group, these side-effects are 
being discussed as potential predictive factors for the effectiveness of EGFR-
inhibitors [25]. 
Even though MT KRAS is predictive for non-response to EGFR-inhibitors, 
only ~50% of patients with WT KRAS respond to EGFR-inhibitors. Thus, 
further factors for predicting response to EGFR-therapy are needed in order 
to avoid EGFR-therapy and its side-effects in patients who do not have the 
potential to benefit [3, 27]. Some preliminary evidence indicates that deter-
mination of BRAF mutations might offer a means of further selecting eligi-
ble patients, because some studies suggest that only patients with mCRC 
WT KRAS and without BRAF mutations benefit from EGFR-inhibition [30-
31]. Though, due to inconsistent results the role of BRAF status in the 
treatment management of mCRC has not been fully established yet [32].  
Besides the positive opinion for first-line therapy, the CHMP also recom-
mended to approve panitumumab in combination with FOLFIRI as second-
line therapy based on improvements in PFS for patients with WT KRAS 
(HR=0.73) [33]. Two meta-analyses also imply that panitumumab is more 
effective in the second- or in subsequent-lines of therapy than in the first-
line setting [3, 27] (but one meta-analysis [3] also included results of the 
PACCE trial). 
To sum up, these findings highlight the fact that despite the availability of 
several different treatment options for mCRC further research is required to 
find the optimal sequence of the available agents, the ideal combination 
with chemotherapy and the optimal duration of treatment [12, 27].  
 
KRAS status predictive 
for (non-)response 
only ˜50% of WT KRAS 
patients respond to 
EGFR-inhibitors 
 
predictive role of BRAF 
status not yet clear 
panitumumab also 
approved for 2nd-line 
mCRC therapy in 
combination with 
FOLFIRI 
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